To Our Shareholders

Christophe Weber  
President and Representative Director  
Takeda Pharmaceutical Company Limited  
1-1, Doshomachi 4-chome  
Chuo-ku, Osaka 540-8645, Japan

Notice of Resolutions at the 144th Ordinary General Meeting of Shareholders

Dear Shareholders:

We hereby report as follows on the matters reported on and the resolutions made at the 144th Ordinary General Meeting of Shareholders of the Company held today.

Matters reported on:

1. Business Report, Consolidated Financial Statements, and Unconsolidated Financial Statements for the 143rd fiscal year (from April 1, 2019 to March 31, 2020)

2. Audit Reports on the Consolidated Financial Statements for the 143rd fiscal year by the Accounting Auditors and the Audit and Supervisory Committee

The contents of these documents were reported.

Matters resolved:

<The Company’s proposals (First to Fourth Proposals)>  

First Proposal: Appropriation of Surplus  
This item was approved as originally proposed. (The year-end dividend is 90 yen (JPY90.00) per share.)

Second Proposal: Election of Twelve (12) Directors who are not Audit and Supervisory Committee Members  
As proposed, Christophe Weber, Masato Iwasaki, Andrew Plump, Costa Saroukos, Masahiro Sakane, Olivier Bohuon, Jean-Luc Butel, Ian Clark, Yoshiaki Fujimori, Steven Gillis, Shiro Kuniya and Toshiyuki Shiga were re-elected, and all twelve (12) Directors who are not Audit and Supervisory Committee Members assumed their respective offices. Masahiro Sakane, Olivier Bohuon, Jean-Luc Butel, Ian Clark, Yoshiaki Fujimori, Steven Gillis, Shiro Kuniya and Toshiyuki Shiga are External Directors defined in Article 2, item 15 of the Companies Act.
Third Proposal: Election of Four (4) Directors who are Audit and Supervisory Committee Members
As proposed, Yasuhiro Yamanaka, Koji Hatsukawa, Emiko Higashi and Michel Orsinger were re-elected, and all four (4) Directors who are Audit and Supervisory Committee Members assumed their respective offices.
Koji Hatsukawa, Emiko Higashi and Michel Orsinger are External Directors defined in Article 2, item 15 of the Companies Act.

Fourth Proposal: Payment of Bonuses to Directors who are not Audit and Supervisory Committee Members
It was proposed and approved that the amount within 1,100 million yen in total be paid to the three (3) Directors (excluding Directors residing overseas and External Directors) in office as of the end of this fiscal year.

<Shareholders’ proposal (Fifth Proposal)>
Fifth Proposal: Election of One (1) Director who is an Audit and Supervisory Committee Member
This item was rejected.

Payment of Dividends
Shareholders who have not designated an account for the automatic transfer of dividend payments are requested to accept their year-end dividends for the 143rd fiscal year at a nearby office of Japan Post Bank Co., Ltd. or Savings Counter of a nearby Post Office within the payment period using the “Receipt of Year-end Dividends” to be sent out.
Shareholders who have designated an account for the automatic transfer of dividend payments are requested to confirm their dividend payments in the “Dividend Account Statement” and the “Confirmation of Designated Account for the Automatic Transfer of Dividend Payments” to be sent out.